Literature DB >> 7998775

Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate.

M F Beal1, D R Henshaw, B G Jenkins, B R Rosen, J B Schulz.   

Abstract

A potential mechanism of neuronal injury in neurodegenerative diseases is a defect in energy metabolism that may lead to slow excitotoxic neuronal death. Consistent with this possibility, we showed that specific inhibitors of the electron transport chain produce excitotoxic lesions in vivo. In the present study we examined whether agents that improve energy metabolism can block lesions produced by the mitochondrial toxin malonate. Striatal lesions produced by the complex II inhibitor malonate were blocked in a dose-dependent manner by oral pretreatment with coenzyme Q10. Administration of nicotinamide by Alzet pump for 1 week attenuated malonate-induced lesions, but riboflavin had no effect. Administration of nicotinamide intraperitoneally just prior to and following induction of the lesions produced dose-dependent neuroprotection. A combination of coenzyme Q10 with nicotinamide was more effective than either compound alone, as shown by both lesion size and magnetic resonance imaging in vivo. Both coenzyme Q10 and nicotinamide blocked adenosine triphosphate depletions and lactate increases. These results confirm that mitochondrial toxins produce striatal excitotoxic lesions by a mechanism involving energy depletion in vivo. Furthermore, they suggest novel neuroprotective strategies that may be useful in the treatment of both mitochondrial encephalopathies and neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998775     DOI: 10.1002/ana.410360613

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  36 in total

Review 1.  Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment.

Authors:  M Flint Beal
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 2.  Antioxidants in Huntington's disease.

Authors:  Ashu Johri; M Flint Beal
Journal:  Biochim Biophys Acta       Date:  2011-11-23

3.  Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease.

Authors:  Jodi L McBride; Shilpa Ramaswamy; Mehdi Gasmi; Raymond T Bartus; Christopher D Herzog; Eugene P Brandon; Lili Zhou; Mark R Pitzer; Elizabeth M Berry-Kravis; Jeffrey H Kordower
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-02       Impact factor: 11.205

4.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

5.  Restoration and putative protection in Parkinsonism.

Authors:  T Archer; A Fredriksson
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

6.  Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects.

Authors:  R T Matthews; L Yang; S Browne; M Baik; M F Beal
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

Review 7.  Mitochondrial matters of the brain: the role in Huntington's disease.

Authors:  C Turner; A H V Schapira
Journal:  J Bioenerg Biomembr       Date:  2010-06       Impact factor: 2.945

Review 8.  Mitochondrial approaches for neuroprotection.

Authors:  Rajnish K Chaturvedi; M Flint Beal
Journal:  Ann N Y Acad Sci       Date:  2008-12       Impact factor: 5.691

9.  Nicotinamide attenuates focal ischemic brain injury in rats: with special reference to changes in nicotinamide and NAD+ levels in ischemic core and penumbra.

Authors:  Fumiko Sadanaga-Akiyoshi; Hiroshi Yao; Sei-ichi Tanuma; Tatsuo Nakahara; Jong Soon Hong; Setsuro Ibayashi; Hideyuki Uchimura; Masatoshi Fujishima
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

10.  Coenzyme Q10 effects in neurodegenerative disease.

Authors:  Meredith Spindler; M Flint Beal; Claire Henchcliffe
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.